Chiesi to Acquire Amryt Pharma for ~$1.48B

Share this
Amryt Pharma


Chiesi to Acquire Amryt Pharma for ~$1.48B


  • Amryt shareholders will receive $14.50 per ADS up front & CVR of ~$2.50 per ADS (in total about $225M) based on the achievement of milestones related to Amryt's product Filsuvez representing a total transaction value of (~$1.25B in upfront consideration & $0.225B in CVR) at a premium of 107% to Amryt ADS’ closing price on Jan 2023. The transaction is expected to close at the end of H1’23
  • The acquisition will accelerate Chiesi’s rare disease medicine portfolio & expertise that helps to provide therapies to patients with rare diseases. The therapy is already approved in the EU for epidemolysis bullosa
  • The Chiesi’s goal is to improve people’s QoL while Amryt focuses to bring innovative products to new markets

Ref: Globenewswire | Image: Amryt Pharma

Related News:- Chiesi Farmaceutici Licenses Tum Bio's NCE401 for $74M

Click here to­ read the full press release 

Senior Editor

Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions